Preterm Birth And PROM Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Preterm Birth And PROM Testing Market Trends and Insights

Rising Global Preterm Birth Incidence

Annual preterm births already exceed 15 million and continue climbing despite medical advances. Asia accounts for more than half of those births, intensifying diagnostic demand in high-population regions^{[2]Constance Agius, “Preterm Birth in Asia,” Frontiers in Pediatrics, frontiersin.org}. Preterm complications cost the United States health system over USD 25 billion each year, spurring payer investment in early detection technologies that reduce neonatal intensive care stays^{[3]National Conference of State Legislatures, “Preterm Birth Costs,” ncsl.org}. Reduction of neonatal mortality has become a central performance metric in national maternal-child health plans, ensuring that budget allocations favor evidence-based diagnostic tools. Advanced maternal age, increasingly common in developed economies, raises baseline risk and keeps demand elevated over the long term.

Technological Advancements in Point-of-Care Diagnostics

Hand-held and bedside analyzers now deliver results within minutes, eliminating laboratory delays during acute obstetric evaluations. Quantitative ultrasound that maps cervical microstructure predicts preterm risk as early as week 23, a notable improvement over history-based assessments. Wearable sensors capturing heart-rate variability supply real-time data feeds that machine-learning models convert into 82% accurate risk scores. Combining artificial intelligence with established biomarkers increases diagnostic specificity while minimizing false positives. Such converged platforms strengthen the role of point-of-care testing within the preterm birth and PROM testing market.

Expansion of Prenatal Screening Programs

Government-funded screening drives steady test adoption in India, Indonesia, and Brazil, where maternal mortality targets align with WHO guidance for comprehensive antenatal care. Cost-efficient assays such as salivary progesterone kits widen rural access. Telehealth portals further extend reach, improving appointment adherence and sample-return rates across dispersed geographies. Standardized national protocols lower per-test costs and stabilize procurement pipelines, benefiting diagnostics vendors with scalable production.

Increasing Healthcare Expenditure on Maternal Care

Hospitalization costs for preterm infants have tripled in economies like South Korea, pushing health systems to prioritize prevention. Clinical studies report an 18% decline in severe neonatal morbidity after integrating maternal biomarker testing into care pathways. Payers favor combined cervical-length measurement and fetal fibronectin testing because the protocol reduces perinatal death by up to 15% while cutting overall costs by 31%. Value-based reimbursement models therefore reinforce spending on early diagnostics within the preterm birth and PROM testing market.

Limited Accessibility in Low-Resource Settings

Diagnostics uptake lags in regions with fragile health infrastructure where preterm birth rates are highest. Shortages of trained personnel and laboratory equipment restrict biomarker testing coverage^{[4]Journal of Global Health, “Diagnostics Access in Low-Resource Settings,” jogh.org}. The cessation of fetal fibronectin supply in remote Australian clinics forced costly patient transfers and highlighted supply chain fragility. Persistent digital divides hamper telehealth solutions, and cold-chain requirements add logistical hurdles. These systemic barriers slow penetration of the preterm birth and PROM testing market in underserved regions.

High Cost of Advanced Diagnostic Tests

Premium assays priced at several hundred USD remain out of reach for many patients because private insurers often exclude preventive maternity testing. Direct-to-consumer models widen access but primarily serve affluent groups. Heightened FDA oversight of laboratory-developed tests raises compliance costs, which manufacturers pass on through higher list prices. Capital outlays for point-of-care devices further deter adoption by smaller clinics in cost-sensitive markets. Unless price and reimbursement hurdles ease, test volumes in the preterm birth and PROM testing market will remain uneven.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: Ultrasound Dominance Drives Current Practice

Ultrasound retained a 38.12% revenue share in 2025, securing its place as the primary modality for cervical-length assessment and fetal surveillance. Quantitative ultrasound now detects microstructural cervical changes that forecast preterm birth risk several weeks earlier than legacy imaging approaches. Biochemical markers, accounting for a smaller 2025 base, exhibit the fastest 9.96% CAGR as clinicians seek objective molecular readouts that complement imaging. Pelvic examination and uterine monitoring continue to serve supportive roles but lack the predictive power of combined biomarker panels. Emerging digital biomarkers and AI-powered analytics promise integrated solutions, signaling longer-term evolution of the preterm birth and PROM testing market.

The widening preference for multimodal assessment underscores a shift toward comprehensive risk profiling. Ultrafast imaging plus biomarker quantification delivers actionable probabilities that drive early interventions such as antenatal steroids. Remote ultrasound systems linked to specialist review extend capability to community settings, while disposable biochemical cartridges simplify bedside workflows. These converging trends strengthen future demand within the preterm birth and PROM testing market size for hybrid platforms that merge imaging with molecular diagnostics.

By Biomarker Category: PAMG-1 Challenges fFN Supremacy

Fetal fibronectin (fFN) commands 41.88% share and remains clinically entrenched due to robust guideline support. Negative fFN results give clinicians 96% confidence that delivery will not occur within two weeks, allowing safe discharge and cost avoidance. Placental alpha-microglobulin-1 (PAMG-1) is growing at a 10.07% CAGR and demonstrates superior predictive performance for delivery within seven days. IGFBP-1 gains traction in low-resource environments because it delivers 91% sensitivity and 82.6% specificity using minimally invasive collection. Cytokines and cell-free RNA represent frontier categories undergoing clinical validation.

Competitive dynamics within the biomarker space are intensifying as novel targets enter multi-analyte panels. Assay developers emphasize high positive predictive value to minimize unnecessary interventions. Laboratories leverage digital PCR for quantitative reads that refine cutoffs and stratify risk tiers, thereby expanding the preterm birth and PROM testing market size for advanced biomarker panels.

By Setting: Laboratory Precision Gains on Point-of-Care Convenience

Point-of-care and emergency settings held 54.76% share in 2025, reflecting the urgency of decision-making when preterm labor is suspected. Ten-minute fFN assays guide steroid administration and maternal transfer within critical windows. Laboratory testing, projected at 10.98% CAGR, benefits from multiplex panels, digital PCR, and next-generation sequencing that outperform single-marker bedside kits. Centralized laboratories can run multi-omics panels that point-of-care systems cannot yet support.

Regulatory focus on laboratory-developed tests reshapes competitive positions. Large reference laboratories absorb compliance overhead and gain volume, whereas smaller point-of-care vendors face higher relative costs. Over time, hybrid care pathways are likely to prevail, with rapid triage tests at the bedside followed by confirmatory lab panels, expanding utilization across both settings in the preterm birth and PROM testing market.

By End User: Home Care Disrupts Hospital-Centric Models

Hospitals and maternity centers accounted for 60.55% revenue in 2025, underscoring their role in complex risk management and emergent care. Maternal-fetal medicine units routinely adopt multi-marker panels alongside imaging. However, home-based care shows 10.92% CAGR as telehealth reimbursement accelerates remote monitoring. Consumer-initiated tests such as Sera Prognostics’ PreTRM enable women to obtain blood draws locally and receive personalized risk scores online. Wearable sensors integrated with cloud analytics add continuous surveillance without clinic visits.

Diagnostic companies adapt by packaging kits suitable for nurse-home visits, by forging alliances with mail-in laboratories, and by embedding apps that couple results with virtual consultations. Ambulatory birth centers bridge hospital and home settings, purchasing mid-cost analyzers that complement basic imaging. These distributed models enlarge patient reach, reinforcing momentum within the preterm birth and PROM testing market.

Geography Analysis

North America held 42.76% of 2025 revenue due to near-universal insurance coverage for key biomarker assays, including new CPT payment for at-home fetal monitoring that removed a traditional access barrier. The United States leads global direct-to-consumer uptake, reflecting strong digital health maturity and patient engagement. Canada’s single-payer system funds national screening programs, ensuring consistent demand. Mexico’s public-private partnerships extend testing to rural areas, though logistic bottlenecks remain. While urban centers showcase high penetration, Indigenous and remote communities still report lower utilization, indicating pockets of unmet need within the preterm birth and PROM testing market.

Asia-Pacific is the fastest-growing region at 9.28% CAGR through 2031. China channels substantial public funds into maternal-child health and conducts cohort studies across 60 neonatal intensive care units that help validate diagnostics. India’s private providers integrate cost-efficient assays into large antenatal camps, while policy reforms aim to lower out-of-pocket costs. Japan and South Korea drive premium-segment demand for high-sensitivity biomarker panels, supported by advanced hospital networks. Australia’s supply disruptions underscore ongoing infrastructure challenges that vendors must address to capture rural opportunities. Diverse income profiles in the region create segmented pricing strategies across the preterm birth and PROM testing market.

Europe maintains steady expansion on the strength of harmonized clinical guidelines and stable reimbursement. NICE recommendations standardize biomarker use across the United Kingdom, which speeds hospital adoption. Germany and France allocate public budgets for preventive screening, integrating tests into bundled antenatal packages. Italy and Spain deploy point-of-care kits in midwife-led clinics to reduce referral delays. Regulatory clarity encourages innovation, though value assessments remain stringent. Meanwhile, Middle East & Africa and South America register rising attention from multilateral aid programs. Limited infrastructure slows immediate growth, yet unmet clinical need remains pronounced, signaling longer-term upside for the preterm birth and PROM testing market.

Regulatory Landscape

In the United States, preterm birth risk and PROM in vitro diagnostic (IVD) tests are regulated as medical devices by the FDA (CDRH). Requirements cover premarket review (as applicable), establishment registration and device listing, labeling controls, and Quality System Regulation compliance. Clinical laboratories running laboratory-based assays must also meet CLIA '88 quality standards, which affects how these tests are validated, performed, and reported across hospital labs and reference laboratories.

In Europe, these IVDs are governed by Regulation (EU) 2017/746 (IVDR). Many near-patient pregnancy-related tests fall under higher-risk pathways, commonly Class C, which requires mandatory conformity assessment by a Notified Body for CE marking. Ongoing EU Commission guidance from the Medical Device Coordination Group (for example, MDCG 2024-11) and technical expectations such as ISO 17511:2020 for metrological traceability shape evidence packages and documentation quality. That increases compliance overhead while improving comparability of results across settings.

Market Opportunities and Future Outlook

A key whitespace is converting preterm birth risk testing from optional screening into outcomes-linked care pathways, supported by clinical evidence that payers and health systems can act on. In July 2026, Sera Prognostics reported PRIME randomized trial subgroup data showing a 22% relative reduction in NICU admissions in first-time pregnancies using PreTRM Test-guided care. This supports programs that pair risk stratification with standardized interventions and follow-up.

On the PROM side, hospital algorithms still rely on speculum examination and traditional bedside methods (pooling, pH, crystallization). IGFBP-1 or PAMG-1 assays are used as adjunct tools when rupture status is uncertain, which leaves room for products that reduce equivocal results and unnecessary admissions. Development is also moving beyond membrane-rupture confirmation into multiplex infectious-risk workups within the same clinical episode: in January 2026, research on a microfluidic chip-based multiplex PCR approach for reproductive-tract pathogens in PROM patients highlighted the direction toward integrated maternal testing menus. These menus connect triage, infection management, and escalation decisions within labor and delivery workflows.